Scott R. Ward has been named Chairman of the Board of Directors by MAP Pharmaceuticals, replacing Staven A. Elms. MAP plans to submit an NDA for its Levadex inhaled ergotamine for the treatment of migraine headaches within the next few months. Read the company’s press release.
MAP Pharmaceuticals appoints new board chair
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
